AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8442968 — intervention group
Group type: EXPERIMENTAL
Intervention: pancuronium (intubating dose) - Groups A, C, and E
Number of subjects: 90
Study 30796424 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy (tyrosine kinase inhibitor for EGFR mutation-positive patients)
Number of subjects: 8947
Study 30796424 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy (tyrosine kinase inhibitor for ALK-positive patients)
Number of subjects: 8947
Study 30796424 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy monotherapy
Number of subjects: 8947
Study 30796424 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 8947
Study 30796424 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-positive and ALK-positive patients
Number of subjects: 8947
Study 30796424 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 8947
Study 29405495 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded alcohol portrayals
Number of subjects: 758
Study 29405495 — intervention group
Group type: COMPARATOR
Intervention: Unbranded alcohol portrayals
Number of subjects: 758
Study 27319096 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal block (n = 30)
Number of subjects: 60
Study 27319096 — intervention group
Group type: COMPARATOR
Intervention: US-guided caudal epidural block (n = 30)
Number of subjects: 60
Study 23770005 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg golimumab
Number of subjects: 464
Study 23770005 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg golimumab
Number of subjects: 464
Study 23770005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study 22076253 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (5-year treatment)
Number of subjects: 113
Study 22076253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 20608242 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 18600358 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative corticosteroids
Number of subjects: 22
Study 18600358 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber drain
Number of subjects: 22
Study 18600358 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug or drain)
Number of subjects: 22
Study 15765387 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteryx implantation
Number of subjects: 64
Study 15765387 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 64
Study 12351470 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg)
Number of subjects: 3600
Study 12351470 — intervention group
Group type: COMPARATOR
Intervention: Glyburide (15 mg)
Number of subjects: 3600
Study 12351470 — intervention group
Group type: COMPARATOR
Intervention: Metformin (2 g)
Number of subjects: 3600
Study 12351470 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone, Glyburide, Metformin
Number of subjects: 3600
Study 12198782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued to form an image of a specified object (e.g., tiger)
Number of subjects: 0
Study 12198782 — intervention group
Group type: COMPARATOR
Intervention: Instructions encouraged subjects to discard the image and to avoid searching for it
Number of subjects: 0
Study 7498100 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg cholecalciferol (vitamin D3)
Number of subjects: 189
Study 7498100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 1901204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone sodium, 1 g/d intravenously
Number of subjects: 1238
Study 1901204 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole naftate and sodium carbonate, 1 g intravenously every 6 hours
Number of subjects: 1238
Study 7045605 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 30
Study 7045605 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 30
Study 30406883 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 Hz dTMS (HF, 13 patients)
Number of subjects: 33
Study 30406883 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz dTMS (LF, 10 patients)
Number of subjects: 33
Study 30406883 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (Sham, 10 patients)
Number of subjects: 33
Study 28720103 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT-based intervention group
Number of subjects: 0
Study 28720103 — intervention group
Group type: COMPARATOR
Intervention: Conventional intervention group
Number of subjects: 0
Study 26331383 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10/20 mg)
Number of subjects: 447
Study 26331383 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (10/20 mg)
Number of subjects: 447
Study 23847964 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined traditional Chinese medicine and western medicine treatment (antivenom serum 6000 U for 5 days, anti pit viper No. 2 concentrated decoction 300 mL twice to three times daily for 5 days)
Number of subjects: 98
Study 23847964 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese medicine treatment (anti pit viper No. 2 concentrated decoction 300 mL twice to three times daily for 5 days)
Number of subjects: 98
Study 23847964 — intervention group
Group type: COMPARATOR
Intervention: Western medicine treatment (antivenom serum 6000 U for 5 days)
Number of subjects: 98
Study 20676771 — intervention group
Group type: COMPARATOR
Intervention: Mesalamine 500 mg suppository administered BID
Number of subjects: 97
Study 20676771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine 1 g suppository administered QHS
Number of subjects: 97
Study 19643831 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-held manual intervention
Number of subjects: 249
Study 19643831 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 249
Study 17315307 — intervention group
Group type: EXPERIMENTAL
Intervention: HsHMP (250 mg of total anthocyanins per dose)
Number of subjects: 193
Study 17315307 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (10 mg)
Number of subjects: 193
Study 15014181 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4742
Study 15014181 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4742
Study 11259798 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroendocrine reactivity measured by urinary adrenaline and cortisol during work and recovery
Number of subjects: 59
Study 11259798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol reactivity during work and recovery
Number of subjects: 59
Study 11259798 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline baseline level and recovery during the day off-work
Number of subjects: 59
Study 11259798 — intervention group
Group type: EXPERIMENTAL
Intervention: Job characteristics
Number of subjects: 59
Study 9749629 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention vendors using a simple system for water purification and storage, handwashing, and beverage storage (dilute bleach 4.95% free available chlorine, narrow-mouth plastic vessels, handwashing soap, and education).
Number of subjects: 83
Study 9749629 — intervention group
Group type: COMPARATOR
Intervention: Control vendors (no intervention).
Number of subjects: 83
Study 7835373 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg once daily
Number of subjects: 20
Study 7835373 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily
Number of subjects: 20
Study 3076609 — intervention group
Group type: EXPERIMENTAL
Intervention: Frone cream 20,000 IU/g
Number of subjects: 0
Study 3076609 — intervention group
Group type: EXPERIMENTAL
Intervention: Frone eye drops (500,000‐1,000,000 U)
Number of subjects: 0
Study 3076609 — intervention group
Group type: EXPERIMENTAL
Intervention: Frone cream or drops
Number of subjects: 0
Study 3076609 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment of interferon in families
Number of subjects: 0
Study 31418808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual health intervention (n = 38)
Number of subjects: 118
Study 31418808 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol prevention intervention (n = 40)
Number of subjects: 118
Study 31418808 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 40)
Number of subjects: 118
Study 28763892 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage
Number of subjects: 1009
Study 28763892 — intervention group
Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 1009
Study 25728724 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-component quality improvement intervention
Number of subjects: 25000
Study 25728724 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention during baseline period)
Number of subjects: 25000
Study 24207068 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 24 weeks
Number of subjects: 48
Study 24207068 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 48
Study 21777267 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich fibrin (PRF)
Number of subjects: 32
Study 21777267 — intervention group
Group type: COMPARATOR
Intervention: Conventional open flap debridement
Number of subjects: 32
Study 19369030 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 110
Study 19369030 — intervention group
Group type: COMPARATOR
Intervention: Negative posttraumatic cognitions
Number of subjects: 110
Study 16677714 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/day D-cycloserine (DCS)
Number of subjects: 22
Study 16677714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 14984380 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU interferon‐alpha2b plus ribavirin (1000‐1200 mg) for 12 months (Group 1)
Number of subjects: 35
Study 14984380 — intervention group
Group type: COMPARATOR
Intervention: 3 MU interferon‐alpha2b plus ribavirin (1000‐1200 mg) for 12 months (Group 2)
Number of subjects: 35
Study 11352963 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine and mitoxantrone (HAM)
Number of subjects: 471
Study 11352963 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin induction
Number of subjects: 471
Study 11352963 — intervention group
Group type: EXPERIMENTAL
Intervention: Study AML-BFM 93
Number of subjects: 471
Study 11352963 — intervention group
Group type: COMPARATOR
Intervention: Study AML-BFM 93 vs Study AML-BFM 87 for high-risk patients
Number of subjects: 471
Study 11352963 — intervention group
Group type: COMPARATOR
Intervention: Study AML-BFM 93 vs Study AML-BFM 87 for standard-risk patients
Number of subjects: 471
Study 9393903 — intervention group
Group type: EXPERIMENTAL
Intervention: CPM at 0 to 70 degrees (0 to 70 CPM)
Number of subjects: 53
Study 9393903 — intervention group
Group type: EXPERIMENTAL
Intervention: CPM at 0 to 40 degrees (0 to 40 CPM)
Number of subjects: 53
Study 9393903 — intervention group
Group type: COMPARATOR
Intervention: No CPM
Number of subjects: 53
Study 9393903 — intervention group
Group type: EXPERIMENTAL
Intervention: CPM (both 0 to 40 and 0 to 70 degrees)
Number of subjects: 53
Study 9393903 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 to 70 CPM
Number of subjects: 53
Study 7957657 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.016 x 0.022‐inch sectional arches including a reverse closing loop for maxillary canines retraction (mean period 7.75 months)
Number of subjects: 20
Study 7957657 — intervention group
Group type: COMPARATOR
Intervention: 0.016 x 0.022‐inch Gjessing retraction arches for maxillary canines retraction (mean period 6.25 months)
Number of subjects: 20
Study 7957657 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.016 x 0.022‐inch sectional arches with reverse closing loop for mandibular canines retraction (mean period 7.75 months)
Number of subjects: 20
Study 7957657 — intervention group
Group type: COMPARATOR
Intervention: 0.016 x 0.022‐inch Gjessing arches for mandibular canines retraction (mean period 6 months)
Number of subjects: 20
Study 3270085 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporin
Number of subjects: 64
Study 3270085 — intervention group
Group type: COMPARATOR
Intervention: cyclophosphamide
Number of subjects: 64
Study 31787053 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a group‐based behavioral intervention focused on patient activation and engagement (n=332)
Number of subjects: 647
Study 31787053 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=315)
Number of subjects: 647
Study 28396565 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical borneol
Number of subjects: 122
Study 28396565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 26809257 — intervention group
Group type: EXPERIMENTAL
Intervention: Learn to be safe with Emmy and friends™ (5 sessions of 1 hour each)
Number of subjects: 72
Study 26809257 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 72
Study 26809257 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent discussion monitor
Number of subjects: 72
Study 24356256 — intervention group
Group type: EXPERIMENTAL
Intervention: Motavizumab 30 mg/kg
Number of subjects: 118
Study 24356256 — intervention group
Group type: EXPERIMENTAL
Intervention: Motavizumab 100 mg/kg
Number of subjects: 118
Study 24356256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 22572834 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut Balance™ (synbiotic supplement)
Number of subjects: 22
Study 22572834 — intervention group
Group type: COMPARATOR
Intervention: Acacia gum (control)
Number of subjects: 22
Study 19284123 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral-sciatic nerve block
Number of subjects: 1550
Study 19284123 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 1550
Study 19284123 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 1550
Study 17245135 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabond (octyl‐2‐cyanoacrylate)
Number of subjects: 22
Study 17245135 — intervention group
Group type: COMPARATOR
Intervention: Traditional sutures
Number of subjects: 22
Study 15038640 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnification lenses
Number of subjects: 19
Study 15038640 — intervention group
Group type: COMPARATOR
Intervention: Traditional safety glasses
Number of subjects: 19
Study 12581548 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin ER 500-mg tablet QD for 7 days
Number of subjects: 233
Study 12581548 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin IR 250-mg tablet BID for 7 days
Number of subjects: 233
Study 9921849 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient physical rehabilitation for 3 weeks
Number of subjects: 50
Study 9921849 — intervention group
Group type: COMPARATOR
Intervention: Exercises performed at home (control treatment)
Number of subjects: 50
Study 7478086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium, Vecuronium, Atracurium (administered via intramuscular and intravascular routes)
Number of subjects: 0
Study 2403747 — intervention group
Group type: EXPERIMENTAL
Intervention: APDT vaccine
Number of subjects: 82
Study 2403747 — intervention group
Group type: COMPARATOR
Intervention: DTP vaccine
Number of subjects: 82
Study 377819 — intervention group
Group type: EXPERIMENTAL
Intervention: Fumaria-preparation Oddibil
Number of subjects: 85
Study 377819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 30895429 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended gastrectomy
Number of subjects: 587
Study 30895429 — intervention group
Group type: COMPARATOR
Intervention: Standard gastrectomy
Number of subjects: 587
Study 30685166 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion initiated immediately after induction of anesthesia (n=33)
Number of subjects: 69
Study 30685166 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=36)
Number of subjects: 69
Study 28104293 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-led debriefing including performance feedback (n = 10)
Number of subjects: 20
Study 28104293 — intervention group
Group type: COMPARATOR
Intervention: No debriefing (control; n = 10)
Number of subjects: 20
Study 25592987 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic and peanut oral immunotherapy (PPOIT)
Number of subjects: 62
Study 25592987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 24119239 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 21
Study 24119239 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 21
Study 24119239 — intervention group
Group type: EXPERIMENTAL
Intervention: Both active and sham rTMS
Number of subjects: 21
Study 21734254 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical sequencing (HS) model
Number of subjects: 48
Study 21734254 — intervention group
Group type: COMPARATOR
Intervention: Logically sequenced (LS) module
Number of subjects: 48
Study 19332525 — intervention group
Group type: EXPERIMENTAL
Intervention: Deductive treatment (N = 16)
Number of subjects: 32
Study 19332525 — intervention group
Group type: COMPARATOR
Intervention: Inductive treatment (N = 16)
Number of subjects: 32
Study 17879411 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous succinate combined with triple therapy for H pylori eradication
Number of subjects: 86
Study 17879411 — intervention group
Group type: COMPARATOR
Intervention: Ferrous succinate only (Control)
Number of subjects: 86
Study 15346355 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (ISMO) at a dose of 20 mg twice a day for 2 weeks
Number of subjects: 31
Study 15346355 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets for 2 weeks
Number of subjects: 31
Study 11249221 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate fixation plus operative arthroscopy
Number of subjects: 19
Study 11249221 — intervention group
Group type: COMPARATOR
Intervention: Plate fixation only (Control)
Number of subjects: 19
Study 9544901 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH 4.5 IU/m2/day
Number of subjects: 223
Study 9544901 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH 3 IU/m2/day
Number of subjects: 223
Study 9544901 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH 3 IU/m2/day for the first year and 4.5 IU/m2/day thereafter
Number of subjects: 223
Study 9544901 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH therapy (all groups)
Number of subjects: 223
Study 7987887 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole plus scaling and root planing
Number of subjects: 0
Study 7987887 — intervention group
Group type: COMPARATOR
Intervention: Positive-control (placebo) plus scaling and root planing
Number of subjects: 0
Study 1968784 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 200 mg
Number of subjects: 48
Study 1968784 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 100 mg
Number of subjects: 48
Study 1968784 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study 343991 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium fusidate ointment
Number of subjects: 90
Study 343991 — intervention group
Group type: COMPARATOR
Intervention: Oral antibiotic therapy (clindamycin, erythromycin, or flucloxacillin) plus placebo ointment
Number of subjects: 90
Study 343991 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriological investigations
Number of subjects: 90
Study 31503789 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible light field reconstruction method using a conventional camera from random 3D positions and angles.
Number of subjects: 0
Study 27910711 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial injury through hysteroscopy
Number of subjects: 103
Study 27910711 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol without any intervention (Control)
Number of subjects: 103
Study 26087080 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous terbinafine 250 mg daily for 12 weeks
Number of subjects: 76
Study 26087080 — intervention group
Group type: COMPARATOR
Intervention: Pulse terbinafine (3 pulses of 500 mg daily for a week, repeated every 4 weeks)
Number of subjects: 76
Study 23777507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 48
Study 23777507 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 48
Study 21629686 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial secondary task
Number of subjects: 0
Study 21629686 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal secondary task
Number of subjects: 0
Study 21629686 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual secondary task
Number of subjects: 0
Study 21629686 — intervention group
Group type: EXPERIMENTAL
Intervention: High navigational ability
Number of subjects: 0
Study 19304253 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dietary variety (fruits, vegetables, snacks, meat, dairy, soda)
Number of subjects: 109
Study 19304253 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent mothers who purchased groceries
Number of subjects: 109
Study 19304253 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and toddler dietary variety
Number of subjects: 109
Study 18283077 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Agents System (web-based data collection system)
Number of subjects: 290
Study 18283077 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 290
Study 15009861 — intervention group
Group type: EXPERIMENTAL
Intervention: Two coil (low RA) configuration
Number of subjects: 11
Study 15009861 — intervention group
Group type: COMPARATOR
Intervention: Single coil (RV) configuration
Number of subjects: 11
Study 11599156 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (L1)
Number of subjects: 30
Study 11599156 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro combined with 15% to 20% NPH (L2)
Number of subjects: 30
Study 11599156 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin treatment (Control)
Number of subjects: 30
Study 9874860 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 25 mg
Number of subjects: 10